Panel Discussion: Comparing Immune Cell Depletion & Immune Tolerance Therapies to Accelerate Safer, Efficacious Therapies

Time: 1:40 pm
day: Conference Day One Pink Track P2

Details:

  • Expand therapeutic approaches beyond B-cell depletion
  • Highlight safety challenges with depletion in comparison to tolerance with Tregs
  • Explore the long-term biological effects of B-cell depletion and immune reprogramming therapies

Speakers:

Daniel Shelly
Daniel Shelly Daniel Shelly is a member of the Executive Leadership Team at PolTREG, where he leads efforts to advance next-generation T-regulatory cell therapies for autoimmune diseases. Read more
Luke Devey
Luke Devey